Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study
Our preliminary findings suggest that markers of systemic inflammation (such as sCLP) and local destruction of the neuromuscular junction (such as sNfL) may assist in treatment decision-making for gMG patients. Larger, multicenter studies are warranted to validate these results and define their clinical utility.
Authors
- Lea Gerischer (ORCID: https://orcid.org/0000-0001-5746-068X)
- Jan D. Lünemann (ORCID: https://orcid.org/0000-0002-3007-708X)
- Sarah Hoffmann (ORCID: https://orcid.org/0000-0001-9549-2594)
- Meret Herdick (ORCID: https://orcid.org/0000-0003-0119-9499)
- Frauke Stascheit (ORCID: https://orcid.org/0000-0001-5306-7880)
- Daniel Schulze (ORCID: https://orcid.org/0000-0001-9415-2555)
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Philipp Mergenthaler (ORCID: https://orcid.org/0000-0002-9753-6711)
- Paul Triller (ORCID: https://orcid.org/0000-0002-7935-2089)
- Sophie Lehnerer (ORCID: https://orcid.org/0000-0001-9007-027X)
- Maike Stein (ORCID: https://orcid.org/0009-0002-1514-8385)
- Paolo Doksani (ORCID: https://orcid.org/0009-0009-5381-5995)
- Carla Dusemund (ORCID: https://orcid.org/0000-0001-6477-8901)
Institutions
- Humboldt-Universität zu Berlin (DE)
- Zimmer Biomet (Germany) (DE)
- University Hospital Münster (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal of Autoimmunity
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1016/j.jaut.2025.103476
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39